对比增强MRI评估胰腺导管腺癌血管侵犯及可切除性:与胰腺专用CT的比较
该回顾性研究纳入82例胰腺导管腺癌患者,比较对比增强CT与MRI检测血管侵犯及判定可切除性的诊断效能。两位阅片者独立评估腹腔干、肠系膜上、脾及肝总动脉和门静脉、肠系膜上及脾静脉的肿瘤接触程度,并分为可切除、交界可切除或局部晚期。CT与MRI检测血管侵犯的AUC范围分别为0.50-0.89和0.51-0.75,无统计学差异;可切除性分类比例在两种检查间亦无差异。结论认为MRI与胰腺专用CT的诊断效能相当。
要点
- 对比增强MRI检测PDAC血管侵犯的AUC为0.51-0.75,与CT的0.50-0.89无统计学差异。
- MRI与CT在可切除性分类比例上无差异(阅片者1 P=0.48,阅片者2 P=0.15)。
- MRI可作为胰腺专用CT的替代方法评估PDAC血管侵犯和可切除性。
核心结论
- 对比增强MRI检测PDAC血管侵犯和判定可切除性的诊断效能与胰腺专用CT相当。
研究设计与样本
- 回顾性研究纳入82例PDAC患者(平均73岁,46例男性),均于2008年1月至2021年3月接受术前对比增强CT和MRI检查;两位放射科医师独立评估血管侵犯程度和可切除性,以病理或术中发现为参考标准。
诊断标准与关键数值
- 血管侵犯分为无肿瘤接触、实性软组织接触≤180°或实性软组织接触>180°;可切除性分为可切除、交界可切除或局部晚期;CT检测血管侵犯AUC为0.50-0.89,MRI为0.51-0.75(P=0.06至>0.99)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare the diagnostic performance for detecting vascular involvement and determining resectability differences regarding pancreatic ductal adenocarcinoma (PDAC) between contrast-enhanced CT and MRI.
METHODS: This retrospective study evaluated 82 patients (73 years, 46 men) with PDAC who underwent both preoperative contrast-enhanced CT and MRI from January 2008 to March 2021. Two radiologists independently categorized vascular involvements for celiac, superior mesenteric, splenic, and common hepatic arteries, and portal, superior mesenteric, and splenic veins into no tumor contact, solid soft-tissue contact ≤ 180°, or solid soft-tissue contact > 180°. The radiologists also classified resectability into resectable, borderline resectable, or locally advanced. Receiver-operating-characteristic (ROC) analysis was conducted to evaluate the diagnostic performances for detecting vascular involvements which were confirmed by pathological or intraoperative findings. The proportion of resectability classifications was compared between CT and MRI by the Fisher's exact test.
RESULTS: No statistical difference was found in the diagnostic performances for detecting vascular involvement in CT (area under the ROC curve [AUC], 0.50-0.89) and MRI (AUC, 0.51-0.75) (P = 0.06-> 0.99). Resectability on CT were 79% and 68%, 20% and 26%, and 1% and 6% for resectable, borderline resectable, and locally advanced tumors for reviewers 1 and 2; those on MRI were 87% and 81%, 12% and 13%, and 1% and 6%, respectively. The proportion of resectability classifications was not different between CT and MRI (P = 0.48 and = 0.15 for reviewers 1 and 2, respectively).
CONCLUSION: The diagnostic performance for detecting vascular involvement and determining resectability of PDAC on contrast-enhanced MRI were comparable with pancreatic protocol CT.
引用
- Noda, Kawai, Kaga, et al. Vascular involvement and resectability of pancreatic ductal adenocarcinoma on contrast-enhanced MRI: comparison with pancreatic protocol CT. Abdom Radiol (NY). 2022. PMID: 35760922. doi:10.1007/s00261-022-03581-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。